Avenue Therapeutics to Present BAER-101 Preclinical Data at American Society for Experimental Neurotherapeutics (ASENT) 2024 Annual Meeting

Stock Information for Fortress Biotech Inc. 9.375% Series A Cumulative Redeemable Perpetual Preferred Stock

Loading

Please wait while we load your information from QuoteMedia.

More Recent News About Fortress Biotech Inc. 9.375% Series A Cumulative Redeemable Perpetual Preferred Stock

Avenue Therapeutics Announces Last Patient Last Visit in Phase 1b/2a Clinical Trial of AJ201 for the Treatment of Spinal and Bulbar Muscular Atrophy (Kennedy's Disease)
Avenue Therapeutics Reports First Quarter 2024 Financial Results and Recent Corporate Highlights
Avenue Therapeutics Announces Exercise of Warrants for $4.4 Million in Gross Proceeds
Avenue Therapeutics Announces Reverse Stock Split
Avenue Therapeutics to Host Virtual Key Opinion Leader (KOL) Event on April 4, 2024
Avenue Therapeutics Reports Full Year 2023 Financial Results and Recent Corporate Highlights
Avenue Therapeutics Receives Positive Listing Determination from Nasdaq
Sidoti Events, LLC's Virtual January Micro-Cap Conference

Market data content copyright © QuoteMedia. Data delayed at least 15 minutes unless otherwise indicated (view Delay Times for all exchanges). Filings and Fundamentals by Morningstar. Insiders by Morningstar (USA) and SEDI (CDN). Analyst ratings by Zacks. Terms of Use.